|
|
||||||||
Article |
1 From the School of Public Health, University of North Carolina, Chapel Hill.
2 Presented at the 17th Ross Research Conference on Medical Issues, held in San Diego, February 2224, 1998. 3 Address reprint requests to L Arab, 2105e McGavran Greenburg, School of Public Health, CB #7400, University of North Carolina, Chapel Hill, NC 27599-7400. E-mail: lenore{at}unc.edu.
| ABSTRACT |
|---|
|
|
|---|
Key Words: Lycopene cardiovascular disease carotenoid antioxidant LDL
| INTRODUCTION |
|---|
|
|
|---|
-carotene, ß-carotene, and lutein next in capacity. The weakest singlet oxygen quencher of the antioxidants studied was
-tocopherol, which is found in much greater concentrations in many body systems. In the past, this difference in concentration drew attention away from the carotenoids as antioxidants, and carotenoids have been studied in detail only recently. Largely because it can be converted to vitamin A, ß-carotene has been the most intensely studied carotenoid to date. A significant accumulation of observational evidence suggesting that ß-carotene, or foods rich in ß-carotene, may protect against cancer led to several clinical trials involving ß-carotene supplementation (2, 3). However, these trials showed that ß-carotene supplementation either increased or had no effect on the risk of lung cancer in high-risk subjects (46).
The deleterious effects of ß-carotene supplementation are not restricted to lung cancer. Rapola et al (7) found that persons consuming ß-carotene supplements had a 75% increase in fatal coronary heart disease in a comparison with persons not receiving supplements. These researchers found a borderline-significant increase in total coronary events in the ß-carotenesupplemented group but no significant increase in nonfatal coronary events.
Although the results of observational studies seem to suggest that intake of foods rich in ß-carotene (ie, fruit and vegetables) protects against such chronic diseases as cancer and cardiovascular disease, clinical trials have not found ß-carotene to be protective and, in some cases, have even shown a negative effect. This suggests that carotenoids other than ß-carotene may be important in preventing disease or that ß-carotene is acting through some mechanism beyond that of antioxidation.
| FOOD SOURCES AND ABSORPTION OF LYCOPENE |
|---|
|
|
|---|
Tomatoes also contain a significant amount of ß-carotene. In fact, they are the fourth-leading contributor to provitamin A and vitamin A intake in the American diet (9). Tomatoes are also rich in folate and potassium, and there is almost 3 times as much vitamin C as lycopene in a tomato. Thus, in studies of health benefits of tomatoes, one must consider that they are also rich in nutrients other than lycopene.
The mechanism of absorption of lycopene is not completely understood. Studies have shown that lycopene from tomato products appears more readily in the circulation if the tomato is heated and if a source of fat is included with the meal. Plasma lycopene concentrations increased only slightly in a group receiving 180 g tomato juice (containing 12 mg lycopene) daily for 6 wk (10). This finding is supported by other studies showing negligible or only slight increases in plasma lycopene concentrations after consumption of various amounts of unheated tomato juice (11, 12). In one study, however, when heated tomato juice mixed with oil was consumed, serum concentrations of lycopene increased, with a peak 2448 h after ingestion (12). Similarly, Gartner et al (13) found that concentrations of lycopene in the chylomicrons of 5 human subjects increased
3 times as much when they consumed tomato paste as when they consumed raw tomatoes. Thus, the availability and absorption of lycopene depend on the processing and treatment of the food that contains the carotenoid and on the fat content of the meal in which lycopene is consumed.
Because of the abundance of double bonds in its structure, there are potentially 1056 different isomers of lycopene, but only a fraction are found in nature (14, 15). The all-trans-configuration is the usual form of carotenoids, including lycopene, in foods (8). However, Stahl et al (16) found that heating tomato juice resulted in trans-to-cis isomerization of lycopene, and on ingestion of this juice, the cis isomers of lycopene appeared to predominate in human serum over the all-trans isomers. Results from the study by Gartner et al (13) showed that more than half of total lycopene in human serum is in the cis form. At present, the exact functions and relative activities of these different isomers are unknown.
| LYCOPENE AND SMOKING |
|---|
|
|
|---|
20 cigarettes/d) generally had lower serum carotenoid concentrations than did those who quit smoking or smoked <20 cigarettes/d (22). The relation between smoking and serum concentration of lycopene was not consistently inverse, however.
Human plasma directly exposed to gas-phase cigarette smoke for 9 h showed an 80% decline in lycopene concentration (23). The order of depletion of dietary antioxidants was as follows: lycopene >
-tocopherol > trans-ß-carotene > lutein/zeaxanthin = cryptoxanthin >
-tocopherol = retinol. In an observational study (n = 91), Pamuk et al (19) found that African American female smokers had 26% lower serum lycopene concentrations than did nonsmokers after adjustment for dietary intake of lycopene and other potential confounders.
The design and results of the study by Pamuk et al are summarized in Table 1
(19), as are 5 other studies in which no effect of smoking on plasma lycopene concentrations was found. Peng et al (24) found that plasma concentrations of ß-carotene,
-carotene, lutein, zeaxanthin, cryptoxanthin, and cis-ß-carotene, but not lycopene, were lower in smokers than in nonsmokers even at the same level of intake. In another study, Brady et al (25) found that serum lycopene was not significantly lower in smokers than in nonsmokers, even though dietary intake of lycopene was lower in smokers. Rao and Agarwal (26) also reported that serum lycopene concentrations did not differ significantly between nonsmokers and habitual smokers. In a sample of men aged 2555 y, no significant differences in plasma lycopene concentrations were observed between smokers, tobacco chewers, and nonusers (27). Hininger et al (28) also found no significant difference in plasma lycopene concentrations between a sample of 11 smokers and 11 nonsmokers. Thus, there is evidence that smoking status is not inversely related to circulating concentrations of lycopene in humans.
|
| BIOLOGICAL ACTIVITY OF LYCOPENE |
|---|
|
|
|---|
Steinberg and Chait (30) found that supplementing smokers' diets with an antioxidant-rich tomato-based juice for 4 wk resulted in significantly increased conjugated diene (CD) lag time, decreased CD propagation rate, and decreased breath pentane excretion compared with that in subjects given a placebo juice. Although it is impossible to separate the effects of lycopene from those of the other antioxidants added to the juice, the authors suggested that lycopene intakes correlated most closely with inhibition of LDL oxidation.
In another intervention study, 22 subjects (11 smokers, 11 nonsmokers) consumed a diet with increased fruit and vegetables, supplying
10 mg ß-carotene, 10 mg lycopene, and 10 mg lutein daily for 2 wk (28). The investigators observed an increase in CD lag time of 14% in smokers and 28% in nonsmokers after the supplementation. Again, these results cannot be attributed to lycopene alone, but they contribute to the evidence that carotenoids may protect against diseases related to oxidative stress.
Romanchik et al (31) isolated LDL samples from 5 persons and enriched them with ß-carotene, lycopene, and lutein to determine whether this would have an effect on LDL oxidation. On copper-mediated oxidation of the LDL, the carotenoids were destroyed before substantial amounts of lipid peroxidation products were formed, providing further evidence that these pigments may be working as antioxidants. Although lycopene was the most rapidly destroyed of the carotenoids studied, only the LDL enriched with ß-carotene exhibited increased CD lag time. In a separate study of LDL from 11 different persons, the same researchers actually found increased oxidation of LDL (as measured by the ferrous oxidationxylenol orange assay) on enrichment with lycopene and lutein, indicating that the relation between lycopene and LDL oxidation is complex (32).
An intriguing nonantioxidant function of lycopene was shown in vitro and in humans. Fuhrman et al (33) showed that the addition of lycopene to macrophage cell lines decreased cholesterol synthesis and increased LDL receptors. Incubation with lycopene in vitro resulted in a 73% decrease in cholesterol synthesis, which was greater than that achieved with ß-carotene. Also, lycopene resulted in a 34% increase in LDL degradation in the cells themselves and approximately a 110% increase in the removal of LDL from the circulation. To test their finding in humans, the investigators fed 6 men 60 mg lycopene/d for 3 mo (approximately equivalent to the amount of lycopene in 1 kg tomatoes). They found a 14% reduction in plasma LDL cholesterol with no significant change in HDL cholesterol. Based on the calculations of Peto et al (34) that there is a 3:1 ratio between lowering of cholesterol and reduction in the risk of myocardial infarction, we would expect an
3040% reduction in risk in persons consuming this amount of lycopene regularly.
| EPIDEMIOLOGIC EVIDENCE FOR A PROTECTIVE EFFECT OF LYCOPENE ON RISK OF HEART DISEASE |
|---|
|
|
|---|
|
Using data from the Malaga center of the EURAMIC study of antioxidant concentrations in adipose tissue and incident myocardial infarction, Gomez-Aracena et al (38) found that the risk of myocardial infarction was 60% lower (odds ratio: 0.39, 95% CI: 0.13, 1.19; P for trend: 0.04) for the highest quintile of adipose lycopene concentration than for the lowest quintile after adjustment for age, family history of coronary heart disease, and cigarette smoking. The results of the total multicenter, multinational EURAMIC data set confirmed this effect. Men with the highest concentrations of lycopene in their adipose tissue biopsy had a 48% reduction in risk of myocardial infarction when they were compared with men with the lowest adipose lycopene concentrations (39). For each quintile increase in lycopene concentration, there was a significant decrease in myocardial infarction risk. This association was partially masked by ß-carotene concentrations. When there was simultaneous control for the 3 primary carotenoids, lycopene was the carotenoid with the major effect.
We, also, stratified data from the EURAMIC study by smoking status and examined the association between adipose lycopene concentrations and myocardial infarction. Higher lycopene concentrations tended to be most protective against myocardial infarction in those men who had never smoked (odds ratio: 0.3 for never smokers, 0.4 for exsmokers, and 0.6 for smokers). This result was contrary to what was expected; if lycopene is protective by being an antioxidant, then its effect should be strongest in smokers who are in a high oxidation state. Thus, the idea that lycopene is working by some other mechanism than as an antioxidant needs further examination. We should also continue to consider that tissue concentrations of lycopene may simply be a marker of some other nutrients or phytochemicals in tomatoes that are protecting the body from disease.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Pawlak and B. Malinauskas The Use of the Theory of Planned Behavior to Assess Predictors of Intention to Eat Fruits Among 9th-Grade Students Attending Two Public High Schools in Eastern North Carolina Family and Consumer Sciences Research Journal, September 1, 2008; 37(1): 16 - 26. [Abstract] [PDF] |
||||
![]() |
M. Napolitano, C. De Pascale, C. Wheeler-Jones, K. M. Botham, and E. Bravo Effects of lycopene on the induction of foam cell formation by modified LDL Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1820 - E1827. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Ignarro, M. L. Balestrieri, and C. Napoli Nutrition, physical activity, and cardiovascular disease: An update Cardiovasc Res, January 15, 2007; 73(2): 326 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, S. Liu, A. D. Pradhan, J. E. Manson, J. E. Buring, J. M. Gaziano, and H. D. Sesso Plasma Lycopene, Other Carotenoids, and the Risk of Type 2 Diabetes in Women Am. J. Epidemiol., September 15, 2006; 164(6): 576 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. O'Kennedy, L. Crosbie, M. van Lieshout, J. I Broom, D. J Webb, and A. K Duttaroy Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 570 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gajic, S. Zaripheh, F. Sun, and J. W. Erdman Jr. Apo-8'-Lycopenal and Apo-12'-Lycopenal Are Metabolic Products of Lycopene in Rat Liver J. Nutr., June 1, 2006; 136(6): 1552 - 1557. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sicilia, A. Bub, G. Rechkemmer, K. Kraemer, P. P. Hoppe, and S. E. Kulling Novel Lycopene Metabolites Are Detectable in Plasma of Preruminant Calves after Lycopene Supplementation J. Nutr., November 1, 2005; 135(11): 2616 - 2621. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zaripheh and J. W. Erdman Jr. The Biodistribution of a Single Oral Dose of [14C]-Lycopene in Rats Prefed Either a Control or Lycopene-Enriched Diet J. Nutr., September 1, 2005; 135(9): 2212 - 2218. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jenab, P. Ferrari, M. Mazuir, A. Tjonneland, F. Clavel-Chapelon, J. Linseisen, A. Trichopoulou, R. Tumino, H. B. Bueno-de-Mesquita, E. Lund, et al. Variations in Lycopene Blood Levels and Tomato Consumption across European Countries Based on the European Prospective Investigation into Cancer and Nutrition (EPIC) Study J. Nutr., August 1, 2005; 135(8): 2032S - 2036S. [Full Text] [PDF] |
||||
![]() |
E. K. Kabagambe, J. Furtado, A. Baylin, and H. Campos Some Dietary and Adipose Tissue Carotenoids Are Associated with the Risk of Nonfatal Acute Myocardial Infarction in Costa Rica J. Nutr., July 1, 2005; 135(7): 1763 - 1769. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Ganji and M. R. Kafai Population Determinants of Serum Lycopene Concentrations in the United States: Data from the Third National Health and Nutrition Examination Survey, 1988-1994 J. Nutr., March 1, 2005; 135(3): 567 - 572. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D Sesso, J. E Buring, E. P Norkus, and J M. Gaziano Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women Am. J. Clinical Nutrition, January 1, 2004; 79(1): 47 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zaripheh, T. W.-M. Boileau, M. A. Lila, and J. W. Erdman Jr [14C]-Lycopene and [14C]-Labeled Polar Products Are Differentially Distributed in Tissues of F344 Rats Prefed Lycopene J. Nutr., December 1, 2003; 133(12): 4189 - 4195. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. D. Sesso, S. Liu, J. M. Gaziano, and J. E. Buring Dietary Lycopene, Tomato-Based Food Products and Cardiovascular Disease in Women J. Nutr., July 1, 2003; 133(7): 2336 - 2341. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wu, S. J. Schwartz, E. A. Platz, S. K. Clinton, J. W. Erdman Jr., M. G. Ferruzzi, W. C. Willett, and E. L. Giovannucci Variations in Plasma Lycopene and Specific Isomers over Time in a Cohort of U.S. Men J. Nutr., June 1, 2003; 133(6): 1930 - 1936. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H Halsted Dietary supplements and functional foods: 2 sides of a coin? Am. J. Clinical Nutrition, April 1, 2003; 77(4): 1001S - 1007. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H Rissanen, S. Voutilainen, K. Nyyssonen, R. Salonen, G. A Kaplan, and J. T Salonen Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study Am. J. Clinical Nutrition, January 1, 2003; 77(1): 133 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Rao Lycopene, Tomatoes, and the Prevention of Coronary Heart Disease Experimental Biology and Medicine, November 1, 2002; 227(10): 908 - 913. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. V. Minorsky Plant Physiology, November 1, 2002; 130(3): 1077 - 1078. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |